Suppr超能文献

美国和加拿大的潜伏性结核感染:谁完成了治疗以及原因是什么?

Latent tuberculous infection in the United States and Canada: who completes treatment and why?

作者信息

Hirsch-Moverman Y, Shrestha-Kuwahara R, Bethel J, Blumberg H M, Venkatappa T K, Horsburgh C R, Colson P W

机构信息

Charles P Felton National Tuberculosis Center, ICAP, Mailman School of Public Health, Columbia University, New York City, New York, USA.

Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

出版信息

Int J Tuberc Lung Dis. 2015 Jan;19(1):31-8. doi: 10.5588/ijtld.14.0373.

Abstract

OBJECTIVES

To assess latent tuberculous infection (LTBI) treatment completion rates in a large prospective US/Canada multisite cohort and identify associated risk factors.

METHODS

This prospective cohort study assessed factors associated with LTBI treatment completion through interviews with persons who initiated treatment at 12 sites. Interviews were conducted at treatment initiation and completion/cessation. Participants received usual care according to each clinic's procedure. Multivariable models were constructed based on stepwise assessment of potential predictors and interactions.

RESULTS

Of 1515 participants initiating LTBI treatment, 1323 had information available on treatment completion; 617 (46.6%) completed treatment. Baseline predictors of completion included male sex, foreign birth, not thinking it would be a problem to take anti-tuberculosis medication, and having health insurance. Participants in stable housing who received monthly appointment reminders were more likely to complete treatment than those without stable housing or without monthly reminders. End-of-treatment predictors of non-completion included severe symptoms and the inconvenience of clinic/pharmacy schedules, barriers to care and changes of residence. Common reasons for treatment non-completion were patient concerns about tolerability/toxicity, appointment conflicts, low prioritization of TB, and forgetfulness.

CONCLUSIONS

Less than half of treatment initiators completed treatment in our multisite study. Addressing tangible issues such as not having health insurance, toxicity concerns, and clinic accessibility could help to improve treatment completion rates.

摘要

目的

评估美国/加拿大一项大型前瞻性多中心队列研究中潜伏性结核感染(LTBI)治疗的完成率,并确定相关风险因素。

方法

这项前瞻性队列研究通过对在12个地点开始治疗的患者进行访谈,评估与LTBI治疗完成相关的因素。在治疗开始时以及完成/终止时进行访谈。参与者根据每个诊所的程序接受常规护理。基于对潜在预测因素和相互作用的逐步评估构建多变量模型。

结果

在1515名开始LTBI治疗的参与者中,1323人有治疗完成情况的信息;617人(46.6%)完成了治疗。完成治疗的基线预测因素包括男性、外国出生、认为服用抗结核药物不会有问题以及拥有医疗保险。与没有稳定住房或没有每月提醒的参与者相比,居住稳定且收到每月预约提醒的参与者更有可能完成治疗。未完成治疗的治疗结束时预测因素包括严重症状以及诊所/药房日程安排的不便、就医障碍和居住地变更。治疗未完成的常见原因是患者对耐受性/毒性的担忧、预约冲突、对结核病的重视程度低以及健忘。

结论

在我们的多中心研究中,不到一半的开始治疗者完成了治疗。解决诸如没有医疗保险、对毒性的担忧以及诊所可及性等实际问题有助于提高治疗完成率。

相似文献

1
Latent tuberculous infection in the United States and Canada: who completes treatment and why?
Int J Tuberc Lung Dis. 2015 Jan;19(1):31-8. doi: 10.5588/ijtld.14.0373.
4
Latent TB infection treatment acceptance and completion in the United States and Canada.
Chest. 2010 Feb;137(2):401-9. doi: 10.1378/chest.09-0394. Epub 2009 Sep 30.
5
Treatment completion for latent tuberculosis infection in Norway: a prospective cohort study.
BMC Infect Dis. 2018 Nov 19;18(1):587. doi: 10.1186/s12879-018-3468-z.
6
Risk factors for treatment default in close contacts with latent tuberculous infection.
Int J Tuberc Lung Dis. 2014 Apr;18(4):421-7. doi: 10.5588/ijtld.13.0688.
8
Female sex and discontinuation of isoniazid due to adverse effects during the treatment of latent tuberculosis.
J Infect. 2013 Nov;67(5):424-32. doi: 10.1016/j.jinf.2013.07.015. Epub 2013 Jul 8.

引用本文的文献

3
Factors Associated With the Discontinuation of Two Short-Course Tuberculosis Preventive Therapies in Programmatic Settings in the United States.
Open Forum Infect Dis. 2024 Jun 6;11(6):ofae313. doi: 10.1093/ofid/ofae313. eCollection 2024 Jun.
4
Isoniazid use, effectiveness, and safety for treatment of latent tuberculosis infection: a systematic review.
Rev Soc Bras Med Trop. 2024 Mar 25;57:e004022024. doi: 10.1590/0037-8682-0504-2023. eCollection 2024.
5
Tuberculosis in United States-Bound Follow-to-Join Asylees, 2014-2019.
Am J Trop Med Hyg. 2024 Mar 26;110(5):999-1005. doi: 10.4269/ajtmh.23-0233. Print 2024 May 1.
6
Latent tuberculosis infection treatment completion in Biscay: differences between regimens and monitoring approaches.
Front Med (Lausanne). 2023 Oct 31;10:1265057. doi: 10.3389/fmed.2023.1265057. eCollection 2023.

本文引用的文献

1
Female sex and discontinuation of isoniazid due to adverse effects during the treatment of latent tuberculosis.
J Infect. 2013 Nov;67(5):424-32. doi: 10.1016/j.jinf.2013.07.015. Epub 2013 Jul 8.
3
Latent TB infection treatment acceptance and completion in the United States and Canada.
Chest. 2010 Feb;137(2):401-9. doi: 10.1378/chest.09-0394. Epub 2009 Sep 30.
6
Prevalence of tuberculosis infection in the United States population: the national health and nutrition examination survey, 1999-2000.
Am J Respir Crit Care Med. 2008 Feb 1;177(3):348-55. doi: 10.1164/rccm.200701-057OC. Epub 2007 Nov 7.
7
Setting the agenda: a new model for collaborative tuberculosis epidemiologic research.
Tuberculosis (Edinb). 2007 Jan;87(1):1-6. doi: 10.1016/j.tube.2005.12.003. Epub 2006 Aug 8.
8
Predicting non-completion of treatment for latent tuberculous infection: a prospective survey.
Am J Respir Crit Care Med. 2006 Sep 15;174(6):717-21. doi: 10.1164/rccm.200510-1667OC. Epub 2006 Jun 29.
9
The scope and impact of treatment of latent tuberculosis infection in the United States and Canada.
Am J Respir Crit Care Med. 2006 Apr 15;173(8):927-31. doi: 10.1164/rccm.200510-1563OC. Epub 2006 Jan 19.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验